{Reference Type}: Journal Article
{Title}: Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria.
{Author}: Rubeiz CJ;Asero R;Betschel S;Craig T;Grumach A;Hide M;Lang D;Levin M;Longhurst H;Magan E;Maurer M;Saini R;Sussman G;Toubi E;Van DN;Zuberier T;Bernstein JA;
{Journal}: World Allergy Organ J
{Volume}: 17
{Issue}: 1
{Year}: 2024 Jan
{Factor}: 5.516
{DOI}: 10.1016/j.waojou.2023.100858
{Abstract}: <B>UNASSIGNED: </B>Chronic spontaneous urticaria (CSU) is a common condition treated by allergist/immunologists, but the only FDA-approved biologic medication, omalizumab, may be underutilized globally.<BR><B>UNASSIGNED: </B>This study was performed to determine the global prescription of omalizumab for treatment of CSU by allergists/immunologists.<BR><B>UNASSIGNED: </B>Anonymous questionnaire surveys were distributed online to World Allergy Organization (WAO) members worldwide. Categorical data were analyzed for descriptive analysis using one-way frequency tabulation in SAS 9.4.<BR><B>UNASSIGNED: </B>There were 348 respondents (43 missing data); Average age 51 (range 28-90); M/F 48%/52%. 58% had > 15 years of clinical experience and 10% < 5; 42% worked in private clinics, 36% public hospitals, 24% academia, 18% private hospitals, and 4% in community practice. Eighty-two percent (82%) prescribed omalizumab for CSU patients and use of omalizumab was highest among young practitioners. The most significant barriers were cost (63%) and restricted formulary (24%). Drug safety (63%) and chances of adverse events (47%) were the most significant factors deciding treatment. Twenty-two percent (22%) reported 80-100% of CSU patients were complete responders to omalizumab; 34% preferred increasing frequency (q 2-weeks), and 18% preferred increasing dose (600 mg q 4-weeks) for partial or non-responders. UAS7, UCT, and CU-QoL were used to assess CSU by 55%, 29%, and 25% of respondents, respectively. Autoimmune thyroid disease (62%), thyroid abnormality (43%) and allergic rhinitis (35%) were the most frequent comorbidities reported.<BR><B>UNASSIGNED: </B>Most clinicians favored omalizumab over other potential treatments due to safety. Although younger clinicians were more likely to prescribe omalizumab, cost and formulary access were major barriers. Only 22% of respondents reported 80% or greater of their patients had complete response to omalizumab, indicating the need for novel CSU therapies.